Transparency Market Research

U.S. Bacterial Conjunctivitis Drugs Market: Segmental Highlights and Table of Content (2012 – 2024)

U.S. Bacterial Conjunctivitis Drugs Market: Steep Decline Estimated on Account of Patent Expiry of Key Drugs.


Albany, NY -- (SBWIRE) -- 12/11/2017 -- According to Transparency Market Research, the U.S. bacterial conjunctivitis drugs market will be worth US$439.8 mn by 2024. This will be a decrease from the previous years as the generic variants encroach the market of bacterial conjunctivitis drugs. On the basis of drug class, the topical fluoroquinolones segment is leading in terms of demand. However, the demand for topical fluoroquinolones will reduce drastically on account of patent expirations of best selling drugs of this class, including, Moxeza, Vigamox, and Zymaxid. This market segment's worth is estimated to come down to US$286.4 mn by 2024 on account of encroachment by generic variations of these drugs.

Read Report Overview @

The U.S. Bacterial Conjunctivitis Drugs Market is segmented on the basis of expression system

The bacterial conjunctivitis drugs market in the U.S. has been segmented based on various antibacterial drug classes. The market is segmented into major types of antibacterial drugs such as fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones segment has been sub-segmented into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin. Aminoglycosides has been sub-segmented into tobramycin and gentamycin. Macrolides has been divided into erythromycin and azithromycin. The others segment is analyzed cumulatively, considering bacitracin, fusidic acid and ceftriaxone within this class.

The market size for the period from 2012 to 2024 has been provided for each of the major drug classes mentioned above in terms of USD million. Along with the market size that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2012 to 2018 and 2018 to 2024 have also been provided.

Request A Sample Report@

Availability of Affordable Generic Medications to Dampen Growth of Bacterial Conjunctivitis Drugs Market

The report states that the U.S. bacterial conjunctivitis drugs market is likely to experience a patent cliff in the near future. The availability of cost effective generic medicines will hamper the market for bacterial conjunctivitis drugs extensively. There is a dearth of novel compounds available for clinical and preclinical examination. There are very few investigations regarding bacterial conjunctivitis and approval of drugs in the pipeline at present. In addition to this, owing to drug expiry issue, doctors are prescribing a variety of affordable generic medications from the past few years. Ophthalmologists and optometrists generally prescribe antibiotics in the form of eye drops and ointments. All these factors are behind the decline of the U.S. bacterial conjunctivitis drugs market. In addition to all these, patients are aware that conjunctivitis is usually acute and will cure on its own in a few days, limiting the demand for bacterial conjunctivitis drugs.

Herbal Treatment May Prove Profitable

On a positive note however, the shift from pharmacological medicines to herbal treatment options will open doors for growth opportunities in the market. Manufacturers are recommended to develop herbal products for the treatment of bacterial conjunctivitis to earn profit. The growing prevalence of ophthalmic bacterial infection will also help the market's growth. In addition to this, the susceptibility of this infection to spread among all age groups from infants to the elderly will drive the growth prospects for this market in the U.S.

Summary of Table of Content


Executive Summary

U.S. Bacterial Conjunctivitis Drugs Market Overview

U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment


Company Profiles

Get Full Report@